NA-Semax Amidate vs NNZ-2591
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: N-Acetyl Semax Amidate, NA-Semax
NA-Semax Amidate is the stabilized form of Semax, the Russian nootropic peptide derived from a fragment of ACTH. Same modification logic as the Selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. It is the most widely used Semax variant in Western nootropic circles, largely on the strength of that stability argument.
Also: Cyclo-L-glycyl-L-2-allylproline, Cyclic glycine-proline analog
NNZ-2591 is Neuren Pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cGP), a small ring-shaped molecule the body makes when it breaks down IGF-1. It is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: Phelan-McDermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and Angelman and Pitt Hopkins syndromes behind it. Phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | NA-Semax Amidate | NNZ-2591 |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Semax is a synthetic analog of ACTH (4-10), a fragment of adrenocorticotropic hormone that has been stripped of hormonal activity while retaining effects on the brain. Its best-characterized action is a marked increase in BDNF and NGF expression in the hippocampus, which is the mechanistic basis for the memory and neuroprotection claims. It also modulates dopaminergic and serotonergic transmission, and affects the melanocortin system, which is thought to contribute to its effects on attention and motivation. Notably it does this without the HPA axis activation you would expect from something derived from ACTH, because the fragment lacks the region responsible for that. The acetylation and amidation slow degradation by peptidases, so more of the dose survives to act. | Cyclic glycine-proline is thought to fine-tune IGF-1 activity in the brain by changing how IGF-1 binds to its carrier protein IGFBP-3. A 2014 Scientific Reports study proposed that cGP nudges IGF-1 activity up when it is low and down when it is high, a normalizing effect rather than a simple boost. NNZ-2591 adds an allyl group to the proline ring, making it resistant to enzymes and able to reach the brain after oral dosing. Trial protocols also describe reduced neuroinflammation and support for synapse function in animal models. It is a close cousin of trofinetide in spirit (both are small IGF-1-derived molecules from the same company), but the exact way it helps in these genetic syndromes has not been pinned down in humans. |
| Common Dosing | 300-600 mcg daily Once or twice daily, morning and early afternoon | 12 mg/kg twice daily (phase 2 target trial dose) Twice daily |
| Administration | Intranasal is the standard and best-supported route, since it was developed as a nasal formulation | Oral liquid |
| Typical Duration | Community protocols commonly report 2-4 week blocks | 13 weeks in phase 2 and phase 3 trials, with 12-month open-label extensions |
| Best Time to Take | Morning, or morning and early afternoon if split | Twice daily (trial schedule) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Semax has a genuine and reasonably large research base, concentrated in Russia, where it is a registered medicine used for ischemic stroke, cognitive impairment and optic nerve disorders. Animal work consistently supports the BDNF and NGF upregulation, and there is human clinical work in stroke recovery. The important caveat is the same as for Selank: this literature is largely Russian, much of it predates modern trial standards, replication in large Western randomized trials has not happened, and neither the FDA nor the EMA has assessed it. For the amidate variant specifically there is no independent published pharmacology comparing it to standard Semax in humans. The stability modification is chemically sound and widely used, and the assumption that it improves real-world effect is reasonable but unproven. | The human data so far come from three small, open-label phase 2 trials of 13 weeks each, all with twice-daily oral dosing titrated up to a target of 12 mg/kg. In Phelan-McDermid syndrome (18 children, published in Neurology Genetics in 2026), 10 of 14 efficacy measures improved significantly from baseline, including clinician and caregiver global ratings, behavior, sleep and communication, and the drug was well tolerated with mostly mild to moderate side effects. Angelman syndrome (reported August 2024) showed a mean CGI-I of 3.0, with 11 of 13 children rated improved by clinicians. Pitt Hopkins syndrome (reported May 2024) showed improvement in 6 of 11 children on clinician-rated severity. The big caveat: none of these had a placebo group, and rare-disease trials with caregiver-rated outcomes are especially prone to placebo effects. A planned Prader-Willi trial was withdrawn before enrolling anyone. The real test is Koala, a randomized, double-blind, placebo-controlled phase 3 trial in about 160 children aged 3 to 12 with Phelan-McDermid syndrome (first patient dosed February 2026; estimated primary completion late 2027), with an open-label extension started in 2026. The FDA has given the program Fast Track, Rare Pediatric Disease and Orphan Drug designations. Neuren has also started work in neonatal hypoxic-ischemic encephalopathy, which is still preclinical. |
Frequently Asked Questions: NA-Semax Amidate vs NNZ-2591
What is the difference between NA-Semax Amidate and NNZ-2591?
NA-Semax Amidate is a cognitive peptide that na-semax amidate is the stabilized form of semax, the russian nootropic peptide derived from a fragment of acth. same modification logic as the selank variant: acetyl group at one end, amide at the other, both there to stop enzymes chewing it up before it does anything. it is the most widely used semax variant in western nootropic circles, largely on the strength of that stability argument. NNZ-2591 is a cognitive peptide that nnz-2591 is neuren pharmaceuticals' second drug, a synthetic analog of cyclic glycine-proline (cgp), a small ring-shaped molecule the body makes when it breaks down igf-1. it is taken by mouth and is being developed for rare childhood neurodevelopmental disorders: phelan-mcdermid syndrome is furthest along, with the first-ever phase 3 trial in that disease started in late 2025, and angelman and pitt hopkins syndromes behind it. phase 2 results looked encouraging, but they were small open-label studies, so nobody knows yet whether it truly works. The main differences lie in their mechanisms of action and clinical applications.
Which is better, NA-Semax Amidate or NNZ-2591?
Neither is universally "better" - the choice depends on your specific goals. NA-Semax Amidate is typically used for cognitive purposes, while NNZ-2591 is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can NA-Semax Amidate and NNZ-2591 be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using NA-Semax Amidate and NNZ-2591 together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.